Being patient: what delays access to new drugs in Europe?
On average, the first citizen to access a new drug in Belgium will wait 13 months longer for it than someone prescribed the same drug in Germany or the UK, despite an EU-wide licensing process. This suggests that country-specific drug regulation—the ‘fourth hurdle’ faced by drug manufacturers—may go a long way to explaining launch delay across Europe.
Related
Undertaking capital projects: linking risk and return
Whether they relate to the energy transition, the renewal of transport infrastructure, or reversing damage to the environment, our society will increasingly need to undertake large capital projects. It will be important to identify the projects’ risks and determine who is responsible for managing these and reducing their likelihood. Read More
Market differentiation in consumer goods: one size fits all?
Consumer goods have seen significant price rises lately, driving up general inflation levels. Some retailers point to territorial supply restrictions limiting their ability to secure lower wholesale prices—they consider these to be anti-competitive. This article considers two specific economic aspects of this discussion: first, it reflects on the effect… Read More